Skip to main content

Psychopharmacology - A Masters Class

$895.00

Quick Facts

Overview

The Latest CME: Advances in Psychopharmacology

This unique online CME course is designed for experienced clinicians who understand the basic therapeutic mechanisms of psychotropic medications and who are familiar with neurobiological and genetic contributions to psychiatric illnesses. World-renowned faculty focus on treatment of both typical and difficult-to treat child, adolescent, or geriatric psychiatric patients.

 

In Psychopharmacology — A Masters Class, you’ll explore both the interface of medical and psychiatric disorders, and the interface between neurology and psychiatry. The importance of a therapeutic alliance when prescribing psychotropic medications is underscored, as are the hazards and benefits of polypharmacy drug interactions. Catch up on current and emerging treatments of:

  • Schizophrenia or bipolar personality disorders
  • Anxiety spectrum or sleep disorders
  • Alcohol and substance abuse disorders
  • Treatment resistant depression
  • Women’s mental health issues
  • ADHD
  • Borderline personality disorders
  • Eating disorders

Topics / Speakers

Neurobiology for the Practicing Clinician - Including Ketamine, Cannabinoids, Inflammation, and Hormones
Carl Salzman, MD


Neuropsychiatry - Interface Between Neurological and Psychiatric Disorders
Martin A. Samuels, MD


The Interface of Medical and Psychiatric Disorders - Focus on Cancer and Heart Disease
Charles B. Nemeroff, MD, PhD


Pharmacological Treatment of Schizophrenia, Prodrome, First Episode, Relapse, and Recovery
Matcheri S. Keshavan, MD


Panel Discussion
Moderator - Carl Salzman, MD
Panel - Drs. Samuels, Nemeroff, and Keshavan


Latest Advances and Current Treatment of Bipolar Mania and Bipolar Depression
Ross J. Baldessarini, MD DSc (hon)


Advances in Treatment for Refractory Depression
Alan F. Schatzberg, MD


The Latest Tricks of the Trade - What to Do When Nothing Works in the Treatment of Resistant Psychiatric Disorders
Stephan M. Stahl, MD, PhD, DSc (hon)


Panel Discussion
Moderator - Carl Salzman, MD
Panel - Drs. Baldessarini, Schatzberg, and Stahl


Anxiety - Treat the Symptoms or Treat the Disorder When First Line Therapies Fail
Stephan M. Stahl, MD, PhD, DSc (hon)


Evaluation and Pharmacological and CBT Treatment of Sleep Disturbance
John W. Winkelman, MD, PhD


Effective Use of Stimulants in Psychiatry - Adult ADD, Anti-Depressant Augmentation, and Eating Disorders
John Ratey, MD


Child and Adolescent Psychopharmacology - Current and Recent Pharmacologic Treatments
Barbara J. Coffey, MD, MS


Panel Discussion
Moderator - Carl Salzman, MD
Panel - Drs. Winkelman, Sheehan, Ratey, and Coffe


Pharmacological Treatment of Substance Use Disorders - Opioids, Alcohol and Marijuana
Roger D. Weiss, MD


Use of Psychotropic Drugs in the Life Cycle of Women - PMS, Pregnancy, Lactation and Menopause
Ariadna Forray, MD


Geriatric Psychopharmacology - What Every Prescriber Should Know About Treating the Elderly with Medications
Carl Salzman, MD


Panel Discussion
Moderator - Carl Salzman, MD
Panel - Drs. Forray and Weiss

Faculty

Course Directors

Lawrence E. Lifson, MD

Lecturer on Psychiatry

Harvard Medical School

Director, Continuing Education Program

Department of Psychiatry

Beth Israel Deaconess Medical Center

Carl Salzman, MD

Professor of Psychiatry

Harvard Medical School

Professor of Psychiatry

Beth Israel Deaconess Medical Center

Faculty

Ross J. Baldessarini, MD, DSc (hon)

Professor of Psychiatry (Neuroscience)

Harvard Medical School

Director, Psychopharmacology Program

Director, International Consortium for Mood &

Psychotic Disorder Research

McLean Hospital

Barbara J. Coffey, MD, MS

Professor and Chairman

Department of Psychiatry and Behavioral Sciences

Chief, Division of Child and Adolescent Psychiatry

University of Miami Miller School of Medicine

Ariadna Forray, MD

Associate Professor of Psychiatry

Interim Chief, Section of Psychological Medicine

Director, Center for Well-being of Women and Mothers

Director, Adult Sickle Cell Program

Yale School of Medicine

Matcheri S. Keshavan, MD

Stanley Cobb Professor of Psychiatry

Department of Psychiatry

Harvard Medical School

Academic Head of Psychiatry

Department of Psychiatry

Beth Israel Deaconess Medical Center

Charles B. Nemeroff, MD, PhD

Matthew P. Nemeroff Professor and Endowed Chair

Department of Psychiatry and Behavioral Sciences

Mulva Clinic for the Neurosciences

Director, Institute of Early Life Adversity Research

Dell Medical School

The University of Texas at Austin

John Ratey, MD

Associate Professor of Psychiatry (part-time)

Harvard Medical School

Associate Professor of Psychiatry (part-time)

Beth Israel Deaconess Medical Center

Martin A. Samuels, MD

Founding Chair Emeritus

Department of Neurology

Miriam Sydney Joseph Distinguished Professor
of Neurology

Harvard Medicine School

Alan F. Schatzberg, MD

Kenneth T. Norris Jr. Professor

Department of Psychiatry and Behavioral Sciences

Stanford University

David V. Sheehan, MD, MBA

Distinguished University Health Professor Emeritus

University of South Florida College of Medicine

Stephen M. Stahl, MD, PhD, DSc (hon)

Professor of Psychiatry

University of California, San Diego

Honorary Visiting Senior Fellow

University of Cambridge, UK

Roger D. Weiss, MD

Professor of Psychiatry

Harvard Medical School

Chief, Center of Excellence in Alcohol, Drugs,
and Addiction

Director, Alcohol, Drug, and Addiction Clinical
Research Program

McLean Hospital

John W. Winkelman, MD, PhD

Chief, Sleep Disorders Clinical Research Program

Departments of Psychiatry and Neurology

Massachusetts General Hospital

Professor of Psychiatry

Harvard Medical School

Accreditation

Accreditation

The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement

The Harvard Medical School designates this enduring material for a maximum of 14.00 AMA PRA Category 1
Credits.
™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Date of Original Release: May 15, 2021
Termination Date: January 31, 2024 (Please note that AMA PRA Category 1 Credits™ will no longer be issued for the activity after this date)
Estimated Time to Complete: 14.00 hours

 

CME credit is awarded upon successful completion of a course evaluation and post-test.

ACGME Competencies

This course is designed to meet one or more of the following Accreditation Council for Graduate Medical Education Competencies:

  • Patient Care and Procedural Skills
  • Medical Knowledge
  • Practice-Based Learning and Improvement

Disclosure

Harvard Medical School (HMS) adheres to all ACCME Accreditation Criteria and Policies. It is HMS's policy that those who have influenced the content of a CME activity (e.g. planners, faculty, authors, reviewers and others) disclose all relevant financial relationships with commercial entities so that HMS may identify and resolve any conflicts of interest prior to the activity. These disclosures will be provided in the activity materials along with disclosure of any commercial support received for the activity. Additionally, faculty members have been instructed to disclose any limitations of data and unlabeled or investigational uses of products during their presentations.

 

Disclosure information for all individuals in control of the content of the activity is located on the disclosure statement.

Learning Objectives

Upon completion of this activity, participants will be better able to apply:

  • Evaluate the effects of neurotransmitters and genes on psychotropic drug treatment
  • Study the interface between neurology and psychiatry
  • Describe the pharmacologic treatment of schizophrenia with particular reference to the prodromal period and first episode
  • Outline the emerging theories and treatments of bipolar disorder, depression, treatment resistant depression, bipolar depression, stress and anxiety disorder
  • Discuss the role of psychotropic medications in women’s mental health with an emphasis on PMS, pregnancy, nursing, and the postpartum period
  • Review the appropriate use of medications in the treatment of sleep disorders
  • Access psychopharmacologic treatment of eating disorders
  • Summarize the interface between medicine and psychiatric disorders with an emphasis on cardiovascular disease and cancer
  • Review the appropriate use of stimulants in the treatment of attention and ADHD disorders as well as their use as an adjunct to antidepressant treatment
  • Identify psychopharmacologic treatment for the borderline personality disorder
  • Explain the role of psychopharmacology in the treatment of substance use disorders with particular emphasis on alcohol, opiates, and cannabis
  • Recognize when to utilize ECT and TMS for the treatment of depression
  • Discuss standard psychopharmacologic treatments that have now been proven to be ineffective
  • Give examples of the latest advances and problems associated with treatment approaches in the child, adolescent and geriatric populations

Intended Audience

Experienced clinicians in the field of psychopharmacology drawn from the following disciplines: psychiatry, medicine, nursing, nurse practitioners, and psychology.

Quick Facts

a CMEinfo video production

Provider: Harvard Medical School

Course Directors:
Lawrence E. Lifson, MD
Lecturer on Psychiatry
Harvard Medical School
Director, Continuing Education Program
Department of Psychiatry
Beth Israel Deaconess Medical Center

Carl Salzman, MD
Professor of Psychiatry
Harvard Medical School
Professor of Psychiatry
Beth Israel Deaconess Medical Center

Credits: Earn up to 14.00 AMA PRA Category 1 Credits

 

Overview

Specialties

Topics / Speakers

Faculty

Accreditation

Further Information

Further Information

Further Information

Reviews

SKU: PSV456E0